Astellas Pharma US, Inc.
NEWS
There were a fair number of clinical trial announcements last week. Here’s a look.
The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The U.S. FDA had a very packed calendar for this week, but almost everything on it was under a Priority Review pathway.
Astellas Pharma is building on a 2019 collaborative relationship and snapping up California-based iota Biosciences and that company’s bioelectronics technology in order to accelerate its Rx+ business.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Roxadustat was non-inferior to Aranesp in hemoglobin levels during the first 24 weeks of treatment, which was the trial’s primary endpoint.
Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.
Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
JOBS
IN THE PRESS